Epix Pharmaceuticals, Inc. announced that its shareholders have voted to approve the company's merger with Predix Pharmaceuticals Holdings, Inc., which was previously announced on April 3, 2006, as well as each of the other proposals related to the merger. In addition, the shareholders of Predix also approved the transaction. The companies expect that the merger will close today, August 16th, an Expix release said.

The combined company will be known as Epix, and is expected to continue to trade on NASDAQ under the symbol "Epix". Following the closing of the transaction, management of the combined company will provide information for a conference call and webcast.

"The vision we had when we initiated the merger with Predix can now start to become reality," stated Chris Gabrieli, chairman of the board of Epix. "We are excited about the potential of the combined company, and look forward to the continuing progress of both Epix's contrast agents and Predix's therapeutic compounds."

Epix Pharmaceuticals, Inc., based in Cambridge, MA, discovers and develops innovative pharmaceuticals for imaging that are designed to transform the diagnosis, treatment and monitoring of disease. EPIX uses its proprietary Target Visualization Technology to create imaging agents targeted at the molecular level, designed to enable physicians to use Magnetic Resonance Imaging (MRI) to obtain detailed information about specific disease processes.

Predix Pharmaceuticals Holdings, Inc., based in Lexington, MA, is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels.